Pain related to more severe motor symptoms, phosphodiesterase 10A loss seen early, novel therapy shows promise, and other recent findings are summarized here.
FDA Approves Sprinkle Formulation of Neurocrine Biosciences’ Valbenazine for Tardive Dyskinesia or Huntington disease Chorea
Paradigm Shift in Parkinson’s Disease Diagnosis
This Week on NeurologyLive® — April 29, 2024
Episode 108: Advancing the Genetic Pool of Parkinson Disease
NeurologyLive® Clinician of the Month Spotlight: Kelly Papesh, DNP, APRN, FNP-BC
NeurologyLive® Friday 5 — April 26, 2024